KR890011895A - 세팔로스포린 염 및 주사용 조성물 - Google Patents
세팔로스포린 염 및 주사용 조성물 Download PDFInfo
- Publication number
- KR890011895A KR890011895A KR1019890000493A KR890000493A KR890011895A KR 890011895 A KR890011895 A KR 890011895A KR 1019890000493 A KR1019890000493 A KR 1019890000493A KR 890000493 A KR890000493 A KR 890000493A KR 890011895 A KR890011895 A KR 890011895A
- Authority
- KR
- South Korea
- Prior art keywords
- salt
- methyl
- crystalline
- aminothiazol
- carboxylate
- Prior art date
Links
- -1 Cephalosporin salts Chemical class 0.000 title claims description 12
- 229930186147 Cephalosporin Natural products 0.000 title 1
- 229940124587 cephalosporin Drugs 0.000 title 1
- 239000007972 injectable composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000006069 physical mixture Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 150000007529 inorganic bases Chemical class 0.000 claims 3
- 231100000252 nontoxic Toxicity 0.000 claims 3
- 230000003000 nontoxic effect Effects 0.000 claims 3
- 150000007530 organic bases Chemical class 0.000 claims 3
- 235000011007 phosphoric acid Nutrition 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 125000003368 amide group Chemical group 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000008025 crystallization Effects 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical class OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 KBr로 희석시킨 결정성 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도]-3-(1-메틸-1-피롤리디노)메틸]-3-세펨-4-카르복실레이트 술페이트 염에 대해 측정한 적외선 스펙트럼을 그래프로 나타낸 도면.
제2도는 KBr로 희석시킨 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도]-3-[1(1-메틸-1-피롤리디노)메틸]-3-세펨-4-카르복실레이트의 결정성 세스키포스페이트염에 대해 측정한 적외선 스펙트럼을 그래프로 나타낸 도면.
제3도는 KBr로 희석시킨 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도]-3-[(1-메틸-1-피롤리디노)메틸]-3-세펨-4-카르복실레이트의 결정성 디포스페이트염에 대해 측정한 적외선 스펙트럼을 그래프로 나타낸 도면.
Claims (19)
- 황산, 이질산, 일염산, 및 이염산부가염,그리고 1.5-2몰 당량의 H3PO4를 함유하는 오르토인산 부가염 중에서 선택하는 것이 특징인 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도[-3-[(1-메틸-1-피롤리디노)메틸]-3-세펨-4-카르복실레이트의 열에 안정한 결정성 염 또는 그의 용매 화합물.
- 제1항에 있어서, 황산, 일염산, 이염산 및 오르토인산 부가염중에서 선택된 것이 특징인 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도[-3-[(1-메틸-1-피롤리디노)메틸]-3-세펨-4-카르복실레이트의 열에 안정한 결정성염 또는 그의 용매 화합물.
- 주사가능한 농도로 물로 희석할때 혼합물의 PH를 약3.5 내지 약7로 제공하는 비율 만큼의 약리적으로 허용되는 비독성의 유기 또는 무기 염기와 청구범위 제1항의 염과의 물리적 혼합물.
- 제3항에 있어서, 주사가능한 농도로 물로 희석할때 염과 염기가 PH를 약4 내지 약6의 범위로 제공하는 비율로 존재하는 것이 특징인 약리적으로 허용되는 비독성의 유기 또는 무기 염기와 청구범위 제1항의 염과의 물리적 혼합물.
- 제4항에 있어서, 염기가 L (+) 리신인것이 특징인 약리적으로 허용되는 비독성의 유기 또는 무기 염기와 청구범위 제1항의 염과의 물리적 혼합물.
- 제4항에 있어서, 염기가 L (+) 아르기닌인것이 특징인 약리적으로 허용되는 비독성의 유기 또는 무기 염기와 청구범위 제1항의 염과의 물리적 혼합물.
- 다음의 단계, 즉 (a)(i)적어도 1몰당량의 황산과 (ii) 황산부가염에 상응하는 쌍성이온과의 혼합물을 제조하고, (b) 혼합물중 쌍성이온이 25mg/ml미만의 농도로 존재하는 경우, 유기용매의 존재하에서 결정화를 일으키는 방식으로 황산부가염의 결정화를 일으켜, (c) 결정성 황산부가염을 분리시키는 단계로 이루어짐을 특징으로 하는 황산가부염의 제조방법.
- 제7항에 있어서, (b) 단계를 유기 용매가 없는 수성매질에서 수행하는 것이 특징인 황산부가염의 제조방법.
- 제8항에 있어서, (a) 단계에서 쌍성이온을 혼합물중에 500mg/ml 미만의 농도로 존재하게 하는 양으로 사용하는 것이 특징인 황산부가염의 제조방법.
- 제7항에 있어서, (a) 단계에서 사용되는 쌍성이온의 양이 혼합물중 25mg/ml를 초과하는 농도로 존재하는 양인 것이 특징인 황산부가염의 제조방법.
- 제8항에 있어서, (a) 단계에서 쌍성이온을 혼합물중 약100mg/ml 내지 약200mg/ml의 농도로 존재하는 양으로 사용화는 것이 특징인 황산부가염의 제조방법.
- 제1항에 있어서, 결정성 염이 결정성 황산부가염인 것이 특징인 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미 노아세트아미도]-3-[(1-메틸-1-피롤리디노)메틸]-3-세펨-4-카르복실레이트의 열에 안정한 결정성염.
- 다음의 X선 분말 회절유형을 갖는 것이 특징인 결정성 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도-3-[(1-메틸-1-피롤리디노)메틸]-3-세펨-4-카르복실레이트 슬페이트염.
- 제1항에 있어서, 결정성 염이 결정성 오르토인산 부가염, 및 그의 수화물인 것이 특징인 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도]-3-[(1-메틸-1-피롤리디노)메틸]-3-세펨-4-카르복실레이트의 열에 안정한 결정성염.
- 다음의 X선 분말 회절 유형을 갖는 것이 특징인 결정성 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도]-3-[(1-메틸피롤리디노)-메틸]-3-세펨-4-카르복실레이트인산염.
- 제1항에 있어서, 결정성염이 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도]-3-[(1-메틸피롤리디노)메틸]-3-세펨-4-카르복실레이트 이염산염인 것을 결정성염.
- 제1항에 있어서, 수분을 2.5중량% 내지 7.0중량% 함유하는 것이 특징인 결정성 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도]-3-[(1-메틸피롤리디노)메틸]-3-세펨-4-카르복실레이트 이염산염 수화물.
- 제1항에 있어서, 수분을 2.5중량% 내지 4.1중량% 함유하는 것이 특징인 결정성 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도]-3-[(1-메틸피롤리디노)메틸]-3-세펨-4-카르복실레이트 이염산염 모노히드레이트.
- 제1항에 있어서, 다음의 X-선 분말 회절 유형을 갖는 특징인 결정성 7-[α-(2-아미노티아졸-4-일)-α-(Z)-메톡시이미노아세트아미도]-3-[(1-메틸피롤리디노)메틸]-3-세펨-4-카르복실레이트 이염산염 모노히드레이트.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US144,899 | 1988-01-19 | ||
US07/144,899 US4910301A (en) | 1985-08-05 | 1988-01-19 | Cefepime cephalosporin salts |
Publications (2)
Publication Number | Publication Date |
---|---|
KR890011895A true KR890011895A (ko) | 1989-08-23 |
KR950003612B1 KR950003612B1 (ko) | 1995-04-17 |
Family
ID=22510643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890000493A KR950003612B1 (ko) | 1988-01-19 | 1989-01-18 | 세팔로스포린 염 및 주사용 조성물 |
Country Status (32)
Country | Link |
---|---|
US (1) | US4910301A (ko) |
JP (1) | JPH0725768B2 (ko) |
KR (1) | KR950003612B1 (ko) |
AT (1) | AT399878B (ko) |
AU (1) | AU615509B2 (ko) |
BE (1) | BE1002749A5 (ko) |
CA (1) | CA1298288C (ko) |
CY (1) | CY1663A (ko) |
CZ (1) | CZ281602B6 (ko) |
DD (2) | DD283397A5 (ko) |
DE (1) | DE3901359A1 (ko) |
DK (1) | DK162054C (ko) |
EG (1) | EG18749A (ko) |
ES (1) | ES2012948A6 (ko) |
FI (1) | FI86854C (ko) |
FR (1) | FR2626003B1 (ko) |
GB (1) | GB2213819B (ko) |
GR (1) | GR1001218B (ko) |
HK (1) | HK72292A (ko) |
HU (1) | HU205940B (ko) |
IE (1) | IE67447B1 (ko) |
IT (1) | IT1229528B (ko) |
LU (1) | LU87432A1 (ko) |
NL (1) | NL192266C (ko) |
NZ (1) | NZ227605A (ko) |
OA (1) | OA09227A (ko) |
PT (1) | PT89474B (ko) |
SE (1) | SE505258C2 (ko) |
SG (1) | SG75492G (ko) |
SK (1) | SK281768B6 (ko) |
YU (1) | YU221188A (ko) |
ZA (1) | ZA89407B (ko) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5244891A (en) * | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
DE68917574T2 (de) * | 1988-12-27 | 1994-12-15 | Chugai Pharmaceutical Co Ltd | Reinigungsverfahren für 1,2-Bis(nicotinamido)propan. |
CA2011116C (en) * | 1989-03-06 | 1999-11-16 | Murray A. Kaplan | Lyophilized bmy-28142 dihydrochloride for parenteral use |
DE3919259A1 (de) * | 1989-06-13 | 1990-12-20 | Hoechst Ag | Kristalline cephem-saeureadditionssalze und verfahren zu ihrer herstellung |
US5698703A (en) * | 1991-09-10 | 1997-12-16 | Bristol-Myers Squibb Company | Syn-isomer of thiazolyl intermediate and process for the preparation thereof |
YU81692A (sh) * | 1991-09-10 | 1995-03-27 | Bristol-Myers Co. | Postupak za proizvodnju cefalosporinskog antibiotika |
US5594129A (en) * | 1991-09-10 | 1997-01-14 | Bristol-Myers Squibb Company | Process for the preparation of a cephalosporin antibiotic |
IL103110A (en) * | 1991-09-10 | 1997-04-15 | Bristol Myers Squibb Co | Anhydrous process for preparing cefepime dihydrochloride hydrate |
CA2099692C (en) * | 1992-07-24 | 2003-09-30 | Gary M. F. Lim | Process for preparing cephalosporin intermediates |
CA2101571A1 (en) * | 1992-09-08 | 1994-03-09 | Elizabeth A. Garofalo | Crystalline dihydrate of a cephalosporin dihydrate salt and injectable compositions thereof |
US5391729A (en) * | 1992-09-08 | 1995-02-21 | Bristol-Myers Squibb Company | Crystalline dihydrate of a cephalosporin salt |
US5401842A (en) * | 1992-09-08 | 1995-03-28 | Bristol-Myers Squibb Company | Injectable compositions of a cephalosporin dihydrate salt |
JPH0840907A (ja) | 1994-08-03 | 1996-02-13 | Meiji Seika Kaisha Ltd | セファロスポリン注射剤 |
WO2005094800A2 (en) * | 2004-03-31 | 2005-10-13 | Lupin Ltd. | A co-precipitated cefepime composition and process for preparation thereof |
EP1773845A1 (en) * | 2004-07-16 | 2007-04-18 | Hetero Drugs Limited | Process for preparing pure cephalosporine intermediates |
ITMI20051684A1 (it) * | 2005-09-13 | 2007-03-14 | Harvest Lodge Ltd | Procedimento per la produzione del dicloridrato di amminoacidi |
ITMI20060422A1 (it) * | 2006-03-09 | 2007-09-10 | Harvest Lodge Ltd | Procedimento diretto per la produzione del dicloridrato di un amminoacido |
US8151846B2 (en) * | 2006-12-15 | 2012-04-10 | Center Line Wheel Corporation | Wheel having inner bead-lock |
TWI400243B (zh) * | 2009-07-20 | 2013-07-01 | Intervet Int Bv | 製造西喹諾(cefquinome)粒子的方法 |
CN103304580B (zh) * | 2013-06-09 | 2014-07-09 | 四川省惠达药业有限公司 | 一种盐酸头孢吡肟化合物、其制备方法及其药物组合物 |
CN108463461B (zh) * | 2015-12-10 | 2021-11-19 | 奈加-Rgm制药有限公司 | 头孢烯化合物、其制备和用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029655A (en) * | 1975-04-11 | 1977-06-14 | Eli Lilly And Company | Method of preparing stable sterile crystalline cephalosporins for parenteral administration |
JPS55151588A (en) * | 1979-05-14 | 1980-11-26 | Takeda Chem Ind Ltd | Preparation of cephalosporin salt crystal |
CH654010A5 (de) * | 1979-05-25 | 1986-01-31 | Glaxo Group Ltd | Zwischenprodukte zur verwendung bei der herstellung von cephalosporin-antibiotika. |
US4329453A (en) * | 1979-10-02 | 1982-05-11 | Glaxo Group Limited | Cephalosporin antibiotic |
CA1213882A (en) * | 1982-03-04 | 1986-11-12 | Jun Okumura | Cephalosporins |
US4406899A (en) * | 1982-03-04 | 1983-09-27 | Bristol-Myers Company | Cephalosporins |
US4525473A (en) * | 1983-03-30 | 1985-06-25 | Bristol-Myers Company | Cephalosporins |
US4537959A (en) * | 1984-03-26 | 1985-08-27 | Eli Lilly And Company | Crystalline cephalosporin antibiotic salt |
US4751295A (en) * | 1984-04-09 | 1988-06-14 | Bristol-Myers Company | Cephalosporin derivatives |
US4749694A (en) * | 1984-04-26 | 1988-06-07 | Merck & Co., Inc. | Novel lysine esters used as absorption |
FR2585705B1 (fr) * | 1985-08-05 | 1989-01-13 | Bristol Myers Co | Sels de cephalosporine et compositions injectables |
US4808617A (en) * | 1985-12-18 | 1989-02-28 | Bristol-Myers Company | Lyophilized or precipitated cephalosporin zwitterion and salt combination |
US4791196A (en) * | 1986-09-26 | 1988-12-13 | Sankyo Company Limited | Crystalline cephem carboxylic acid addition salt |
-
1988
- 1988-01-19 US US07/144,899 patent/US4910301A/en not_active Expired - Lifetime
- 1988-12-06 YU YU02211/88A patent/YU221188A/xx unknown
-
1989
- 1989-01-12 NZ NZ227605A patent/NZ227605A/en unknown
- 1989-01-13 SK SK243-89A patent/SK281768B6/sk unknown
- 1989-01-13 CZ CS89243A patent/CZ281602B6/cs not_active IP Right Cessation
- 1989-01-16 FI FI890213A patent/FI86854C/fi not_active IP Right Cessation
- 1989-01-16 ES ES8900146A patent/ES2012948A6/es not_active Expired - Fee Related
- 1989-01-17 GR GR890100025A patent/GR1001218B/el not_active IP Right Cessation
- 1989-01-17 IT IT8947539A patent/IT1229528B/it active
- 1989-01-18 PT PT89474A patent/PT89474B/pt not_active IP Right Cessation
- 1989-01-18 CA CA000588576A patent/CA1298288C/en not_active Expired - Lifetime
- 1989-01-18 NL NL8900111A patent/NL192266C/nl not_active IP Right Cessation
- 1989-01-18 HU HU89185A patent/HU205940B/hu unknown
- 1989-01-18 LU LU87432A patent/LU87432A1/fr unknown
- 1989-01-18 EG EG2189A patent/EG18749A/xx active
- 1989-01-18 DD DD89325118A patent/DD283397A5/de unknown
- 1989-01-18 KR KR1019890000493A patent/KR950003612B1/ko not_active IP Right Cessation
- 1989-01-18 DE DE3901359A patent/DE3901359A1/de active Granted
- 1989-01-18 DD DD89333774A patent/DD284807A5/de unknown
- 1989-01-18 OA OA59509A patent/OA09227A/xx unknown
- 1989-01-18 ZA ZA89407A patent/ZA89407B/xx unknown
- 1989-01-18 GB GB8901073A patent/GB2213819B/en not_active Expired - Lifetime
- 1989-01-18 FR FR8900553A patent/FR2626003B1/fr not_active Expired - Lifetime
- 1989-01-18 DK DK020789A patent/DK162054C/da not_active IP Right Cessation
- 1989-01-18 AT AT0008589A patent/AT399878B/de not_active IP Right Cessation
- 1989-01-18 BE BE8900051A patent/BE1002749A5/fr active
- 1989-01-18 IE IE14489A patent/IE67447B1/en not_active IP Right Cessation
- 1989-01-18 SE SE8900173A patent/SE505258C2/sv not_active IP Right Cessation
- 1989-01-19 JP JP1008776A patent/JPH0725768B2/ja not_active Expired - Lifetime
- 1989-01-19 AU AU28623/89A patent/AU615509B2/en not_active Expired
-
1992
- 1992-07-24 SG SG754/92A patent/SG75492G/en unknown
- 1992-09-24 HK HK722/92A patent/HK72292A/xx not_active IP Right Cessation
-
1993
- 1993-05-14 CY CY1663A patent/CY1663A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890011895A (ko) | 세팔로스포린 염 및 주사용 조성물 | |
JPS5353691A (en) | 3,7-di-substituted-3-cephem-4 carboxylic acid derivatives, their salts andtheir preparation | |
KR880002530A (ko) | 세팔로스포린염과 주사 가능한 조성물 | |
JPS53149993A (en) | 3,7-disubstituted-3-cephem-4-carboxylic acid derivatives, their salts, and their preparation | |
KR960007599A (ko) | 주사용 세팔로스포린의 안정한 저장성과 용이한 수용성을 갖는 조성물 | |
KR840007731A (ko) | 세팔로스포린 화합물의 제조방법 | |
JPS5334795A (en) | Cephalosporin derivatives and their preparation | |
IL69246A (en) | 7-((2-aminothiazolyl-2-pyrrolidonyl or(piperidonyl)-oxyimino)acetamido)cephem carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them | |
SE8800036L (sv) | Lyofiliserad eller felld kombination cefalosporin-zwitterjon och salt | |
DE2964634D1 (en) | 3,7-disubstituted-2- or -3-cephem-4-carboxylic acid compounds, pharmaceutical compositions containing them and processes for the preparation thereof | |
EP0386668B1 (en) | Lyophilized dihydrochloride of 7-[alpha-(2-aminothiazol-4-yl)-alpha-(Z)-methoxyiminoacetamido]-3-[(1-methyl-1-pyrrolidinium)-methyl]-3-cephem-4-carboxylate | |
PH20392A (en) | Pyridobenzodiazepinones pharmaceutical compositions thereof and method of use thereof | |
KR890002174A (ko) | 삼환성 세팜 화합물, 그의 제조방법 및 용도 | |
JPS53101393A (en) | Cephalosporin derivatives and process for their preparation | |
ES8308331A1 (es) | Un procedimiento de preparacion de cefalosporinas sustituidas en la posicion 3 con un grupo heterociclo-tiometilo. | |
US4680389A (en) | Temperature stable crystalline di(1-methyl-2-pyrralidinone) and di(N-formylpyrrolidine) adducts of cephalosporin derivatives | |
HU182498B (en) | Process for producing 7-bracket-iminoacetamido-bracket closed-3-thiomethyl-ceph-3-eme-4-caraoxylic acid | |
CA1282407C (en) | Crystalline cephem carboxylic acid addition salt | |
JPS53101392A (en) | Cephalosporin derivatives and process for their preparation | |
HU183012B (en) | Process for producing esters and ethers of cepheme carboxylic acid | |
KR910015586A (ko) | 신규한 세팔로스포린 화합물과 그의 제조방법 | |
EP0221719A3 (en) | Novel cephalosporin derivatives, processes for their preparation and pharmaceutical compositions containing them | |
JPS5315395A (en) | Cephalosporin derivatives and their preparation | |
DE3270406D1 (en) | Amidines, process for their preparation, pharmaceutical compounds containing them and their use | |
GB1503310A (en) | Water-soluble triazolylthiomethyl cephem derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090410 Year of fee payment: 15 |
|
EXPY | Expiration of term |